TP53 and breast carcinoma: In two case studies of distinct diseases, human rhinovirus infection (HRV) versus matched healthy controls (n=16 training; n=3 test) and breast cancer tissues harboring TP53 or PIK3CA mutations versus adjacent normal tissue (n=27 training; n=9 test)—this approach achieved 90% precision and recall on an unseen breast cancer test set and 92% precision with 90% recall in rhinovirus fivefold cross-validation.